Valuation
- Market cap
- 271,138,000
- Revenue TTM
- $0
- Net income TTM
- $13,270,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 358,900
- Avg volume
- 507,130
- Day's range
- $2.80 – $3.00
- Shares out
- 90,986,000
- Stochastic %K
- 11%
- Beta
- 0.58
- Analysts
- Strong Sell
- Price target
- $11.82
Company profile
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical...
Show more
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 305 845 2813
- Website
- https://www.sab.bio
- Address
- 777 W 41st St., Miami Beach, United States
Latest news
No headlines yet.
